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Introduction
In adults with inflammatory arthritis, insulin resistance
(IR) is associated with diabetes and cardiovascular disease.
Interleukin-6 (IL-6) is postulated to play a mechanistic
role in IR.
Objectives
To evaluate the degree of IR among children with sys-
temic juvenile idiopathic arthritis (sJIA) and whether
treatment with tocilizumab (TCZ) results in attenuation
of IR in sJIA.
Methods
Patients (pts) from TENDER1 were included if baseline
and wk 6 fasting insulin were measured. Glucocorticoid
tapering was not permitted until wk 6. Insulin sensitivity
was quantified using the homeostatic model of insulin
resistance (HOMA-IR). Pts were classified as having IR
if their HOMA-IR was ≥2.2 U. Change in HOMA-IR
after 6 wks was assessed using paired t-test. Baseline
associations with HOMA-IR and factors predicting
change of HOMA-IR from baseline were assessed using
regression analyses. Factors changing in association with
HOMA-IR change were assessed.
Results
92 pts with sJIA were analysed. 62 were randomised to
TCZ and 30 to placebo, 12 of whom required escape
therapy with TCZ by wk 6. At baseline, 40 pts (43%)
had IR. Baseline HOMA-IR was associated with higher
standardised body mass index and higher IL-6 levels
(b-coefficient [95% CI]: 0.20 [0.05, 0.35] and 0.019
[0.001, 0.038], respectively) but not with JADAS, CRP,
active joint count or presence of fever. Of the 74 pts
who received TCZ, 34 (46%) had IR at baseline, includ-
ing 4 pts who escaped from the placebo arm, compared
with 6/18 (33%) who received only placebo. IR pts trea-
ted with TCZ but not placebo had significant reductions
in HOMA-IR at wk 6 (Table). Across all IR pts,
improvement in JADAS and active joint count was not
associated with improvement in HOMA-IR (b-coeffi-
cient [95% CI]: 0.04 [-0.07, 0.14] and 0.08 [-0.06, 0.22],
respectively).
Conclusion
After only 6 wks of TCZ treatment, HOMA-IR was
improved in IR pts with sJIA in the presence of
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Table 1 Change in HOMA-IR after 6 wks of Treatment in




TCZ (n = 34) -0.2 (-3.8, -0.2) 0.03
PBO (n = 6) 0 (-1.7, 1.6) NS
NS, not significant; PBO, placebo. *paired t-test.
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unchanged glucocorticoid dose. These data support a
mechanistic contribution of IL-6 to IR in vivo in humans.
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